AtriCure, Inc. (NASDAQ:ATRC) reported Q2 2017 earnings this Afternoon, coming in at ($0.21) per share, beating Wall Street’s estimates of ($0.26) per Share. Revenue for the quarter came in at $45.23 million beating analyst estimates of $44.15 million
Analyst Coverage For AtriCure, Inc. (NASDAQ:ATRC)
These are 1 Hold Rating, 7 Buy Ratings .
The current consensus rating for AtriCure, Inc. (NASDAQ:ATRC) is Buy (Score: 2.88) with a consensus target price of $23.25 , a potential (2.47% upside)Recent Insider Trading for AtriCure, Inc. (NASDAQ:ATRC)
- On 5/17/2017 Elizabeth D Krell, Director, sold 10,000 with an average share price of $21.44 per share and the total transaction amounting to $214,400.00.
- On 3/17/2017 Andrew L Lux, SVP, sold 20,000 with an average share price of $18.85 per share and the total transaction amounting to $377,000.00.
- On 11/15/2016 Elizabeth D Krell, Director, sold 10,000 with an average share price of $19.73 per share and the total transaction amounting to $197,300.00.
- On 9/13/2016 Elizabeth D Krell, Director, sold 6,000 with an average share price of $15.93 per share and the total transaction amounting to $95,580.00.
- On 8/17/2016 Elizabeth D Krell, Director, sold 5,000 with an average share price of $15.20 per share and the total transaction amounting to $76,000.00.
- On 3/8/2016 Elizabeth D Krell, Director, sold 10,000 with an average share price of $16.91 per share and the total transaction amounting to $169,100.00.
Recent Trading for AtriCure, Inc. (NASDAQ:ATRC) Shares of AtriCure, Inc. closed the previous trading session at 22.69 down -0.45 -1.94% with 281,453 shares trading hands.